Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics, Inc. KYMR shares rallied 7.8% in the last trading session to close at $40.12. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.6% loss over the past four weeks.Shares gained as investors were impressed by the pipeline updates provided by the company at the J.P. Morgan Annual Healthcare Conference. Kymera has a sound cash position and ended 2024 with an estimated cash of $850 million, which should extend its runway to mid-2027. This company is expected to post quarterly loss of $0.76 per share in its upcoming report, which represents a year-over-year change of -204%. Revenues are expected to be $13.09 million, down 72.7% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Kymera Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Kymera Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Arbutus Biopharma (ABUS), another stock in the same industry, closed the last trading session 5.1% lower at $3.18. ABUS has returned -5.6% in the past month.Arbutus' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. Compared to the company's year-ago EPS, this represents a change of +33.3%. Arbutus currently boasts a Zacks Rank of #3 (Hold).Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Kymera Therapeutics, Inc. (KYMR): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks